Literature DB >> 32291407

(2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?

Chadi G Abdallah1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32291407      PMCID： PMC7414015          DOI： 10.1038/s41386-020-0668-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  (2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?

Authors:  Chadi G Abdallah
Journal:  Neuropsychopharmacology       Date:  2020-04-14       Impact factor: 7.853

2.  Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Authors:  Cristan A Farmer; Jessica R Gilbert; Ruin Moaddel; Jomy George; Lilian Adeojo; Jacqueline Lovett; Allison C Nugent; Bashkim Kadriu; Peixiong Yuan; Todd D Gould; Lawrence T Park; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2020-07       Impact factor: 7.853

3.  Ketamine metabolite pilot study in a suicidal depression trial.

Authors:  Michael F Grunebaum; Hanga C Galfalvy; Tse-Hwei Choo; Michelle S Parris; Ainsley K Burke; Raymond F Suckow; Thomas B Cooper; J John Mann
Journal:  J Psychiatr Res       Date:  2019-08-09       Impact factor: 4.791

4.  Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.

Authors:  Carlos A Zarate; Nancy Brutsche; Gonzalo Laje; David A Luckenbaugh; Swarajya L Vattem Venkata; Anuradha Ramamoorthy; Ruin Moaddel; Irving W Wainer
Journal:  Biol Psychiatry       Date:  2012-04-18       Impact factor: 13.382

5.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

6.  Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.

Authors:  Yukihiko Shirayama; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176
  6 in total
  5 in total

Review 1.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

2.  (2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?

Authors:  Chadi G Abdallah
Journal:  Neuropsychopharmacology       Date:  2020-04-14       Impact factor: 7.853

Review 3.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

4.  Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine.

Authors:  Mireia Tarrés-Gatius; Lluís Miquel-Rio; Leticia Campa; Francesc Artigas; Anna Castañé
Journal:  Transl Psychiatry       Date:  2020-12-10       Impact factor: 6.222

Review 5.  Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.

Authors:  Yan Wei; Lijia Chang; Kenji Hashimoto
Journal:  Mol Psychiatry       Date:  2021-05-07       Impact factor: 15.992
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.